Ranibizumab Medicine 07 December 2022 Extended indication Wet age-related macular degeneration (AMD) Therapeutic value Possible equal value Total cost Registration phase Registered Product Active substance Ranibizumab Domain Neurological disorders Reason of inclusion Biosimilar BS Main indication Eye disorders Extended indication Wet age-related macular degeneration (AMD) Current proprietary name Lucentis (Novartis) Already available biosimilars / generics Proprietary name Ximluci Manufacturer Portfolio holder Mechanism of action Angiogenesis inhibitor Route of administration Unknown Therapeutical formulation Unknown Budgetting framework Intermural (MSZ) Centre of expertise Additional remarks Fabrikant: STADA Arzneimittel AG Registration Registration route Centralised (EMA) Type of trajectory Normal trajectory Particularity Unknown ATMP No Submission date 2021 Expected Registration November 2022 Orphan drug No Registration phase Registered Reimbursement Medicine sluice Additional remarks SPC Lucentis verloopt op 23 juli 2022. September 2022 positieve opinie. Therapeutic value Current treatment options Therapeutic value Possible equal value This assessment does not indicate any potential inclusion in the package. Substantiation Duration of treatment Frequency of administration Dosage per administration References Additional remarks Expected patient volume per year Patient volume Market share is generally not included unless otherwise stated. Maximum patient volume for sluice References Additional remarks Expected cost per patient per year Cost References Additional remarks Potential total cost per year Total cost Total cost for sluice Additional remarks Off label use Off label use Unknown Indications off label use References Additional remarks Indication extension Indication extensions Unknown Indication extensions References Additional remarks Other information Additional remarks